Experience and enlightenment of digital therapeutics management and health insurance payment in Japan
By combing the application status,paths and standards of health insurance payment of digital therapeutics(DTx)in Japan,it is found that the access to DTx in Japan is carried out under the framework of traditional medical devices,benefiting from independent classification management and regulatory strategies,data sharing between industry,academia and research institutes,and rapid development of DTx.However,limited basis of health technology assessment has led to an incomplete evaluation dimension of DTx,and there are potential pitfalls in terms of ethical review and social impacts.In the future,China can explore regional pilots that use real-world evidence as the criterion,try to quickly review and pay,ensure the interests of multiple parties and ethical considerations,and regularly conduct impact assessments to ensure the healthy development of DTx.
digital therapeuticspolicy guaranteehealth insuranceJapan
万方数据
维普
